Story perspectives

AstraZeneca Opens $1B Kendall Square R&D Center in Cambridge

By Drooid · Oct 6, 2026, 6:13 PM UTC · How we work

Summary

Story summary

AstraZeneca opened a new 570,000-square-foot, 18-story R&D center in Kendall Square, Cambridge, Massachusetts.
The facility will house nearly 2,000 researchers and increase the state workforce to about 3,000, a 50 % rise.
AstraZeneca is investing more than $1 billion in Massachusetts, part of a $50 billion U.S. program.
Ten lab floors feature robotics, automation and agentic AI for oncology, cell therapy, COPD, obesity, metabolic and rare diseases.

History

Historical Context

Boston’s biotech roots trace to the 1970s when Biogen launched the region’s first biotechnology firm. Governor Deval Patrick’s 2008 $1 billion Life Sciences Act catalyzed growth, leading to $13.7 billion in venture capital by 2021 and lab space exceeding 41 million square feet by 2022. AstraZeneca’s 2024 $1 billion Cambridge R&D hub leverages this ecosystem for oncology and AI-driven drug discovery.

1 of 2

Story summary

AstraZeneca opened a new 570,000-square-foot, 18-story R&D center in Kendall Square, Cambridge, Massachusetts.
The facility will house nearly 2,000 researchers and increase the state workforce to about 3,000, a 50 % rise.
AstraZeneca is investing more than $1 billion in Massachusetts, part of a $50 billion U.S. program.
Ten lab floors feature robotics, automation and agentic AI for oncology, cell therapy, COPD, obesity, metabolic and rare diseases.

1 / 2